Meeting
2020 ASCO Virtual Scientific Program
Identification and in silico structural insights of rare recurrent EGFR mutations as resistance mechanisms to osimertinib in EGFR-mutated lung cancer.
Authors
N/a Zhoutong
Department of Medical Oncology, Changzhou Cancer Hospital of Soochow University, Changzhou, China
N/a Zhoutong , Changling Wu , Binbin Lu , Ran Cao , Yutong Ma , Hua Bao , Qiuxiang Ou , Xue Wu , Yang Shao , Zhaoxia Wang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Biologic Correlates
Citation
J Clin Oncol 38: 2020 (suppl; abstr 9531)
DOI
10.1200/JCO.2020.38.15_suppl.9531
Abstract #
9531
Poster Bd #
297
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Aumolertinib with chemotherapy or alone compared with osimertinib in patients with EGFR-mutant non–small-cell lung cancer (TREBLE).
First Author: Melissa Lynne Johnson
Poster
2022 ASCO Annual Meeting
Epidemiology and clinical impact of EGFR mutation in patients with lung cancer after radical surgical treatment.
First Author: Maciej Bryl
Poster
2021 ASCO Annual Meeting
Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon EGFR mutations: A real-world cohort study (UpSwinG).
First Author: Satoru Miura
Poster
2019 ASCO Annual Meeting
Mutation and treatment profiles of patients with concurrent EGFR and ALK actionable mutations (muts).
First Author: Jun Zhao